CY1115283T1 - Μονοκλωνο κυκλικο rna και μεθοδος παραγωγης αυτου - Google Patents

Μονοκλωνο κυκλικο rna και μεθοδος παραγωγης αυτου

Info

Publication number
CY1115283T1
CY1115283T1 CY20141100228T CY141100228T CY1115283T1 CY 1115283 T1 CY1115283 T1 CY 1115283T1 CY 20141100228 T CY20141100228 T CY 20141100228T CY 141100228 T CY141100228 T CY 141100228T CY 1115283 T1 CY1115283 T1 CY 1115283T1
Authority
CY
Cyprus
Prior art keywords
strand
circular rna
production
stranded circular
antisense strand
Prior art date
Application number
CY20141100228T
Other languages
English (en)
Inventor
Hiroshi Abe
Yoshihiro Ito
Naoko Abe
Hidekazu Toyobuku
Original Assignee
Riken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riken filed Critical Riken
Publication of CY1115283T1 publication Critical patent/CY1115283T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ένα κυκλικό RNA μονής αλύσου που έχει παρατεταμένη ή βραδείας απελευθερώσεως δράση παρεμβολής του RNA, χαρακτηριζόμενο από το ότι το κυκλικό RNA μονής αλύσου περιλαμβάνει μία αλληλουχία νοηματικού κλώνου, μία αλληλουχία αντινοηματικού κλώνου συμπληρωματική στην αλληλουχία νοηματικού κλώνου, ταυτόσημες ή διαφορετικές αλληλουχίες δύο βρόχων μεταξύ του νοηματικού κλώνου και του αντινοηματικού κλώνου, που συνδέουν τους δύο κλώνους, όπου ο νοηματικός κλώνος και ο αντινοηματικός κλώνος συζεύγνυνται για να σχηματίσουν ένα στέλεχος.
CY20141100228T 2007-05-09 2014-03-24 Μονοκλωνο κυκλικο rna και μεθοδος παραγωγης αυτου CY1115283T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007125045A JP5296328B2 (ja) 2007-05-09 2007-05-09 １本鎖環状ｒｎａおよびその製造方法
EP08764303.7A EP2143792B1 (en) 2007-05-09 2008-05-09 Single-stranded cyclic RNA, and method of production thereof

Publications (1)

Publication Number Publication Date
CY1115283T1 true CY1115283T1 (el) 2017-01-04

Family

ID=40002313

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100228T CY1115283T1 (el) 2007-05-09 2014-03-24 Μονοκλωνο κυκλικο rna και μεθοδος παραγωγης αυτου

Country Status (26)

Country Link
US (3) US20100137407A1 (el)
EP (1) EP2143792B1 (el)
JP (1) JP5296328B2 (el)
KR (1) KR101525633B1 (el)
CN (1) CN101679962A (el)
AR (1) AR072034A1 (el)
AU (1) AU2008250075B2 (el)
BR (1) BRPI0811440A2 (el)
CA (1) CA2685994A1 (el)
CO (1) CO6241167A2 (el)
CY (1) CY1115283T1 (el)
DK (1) DK2143792T3 (el)
ES (1) ES2446040T3 (el)
HK (1) HK1135140A1 (el)
HR (1) HRP20140170T1 (el)
IL (1) IL201975A (el)
MX (1) MX2009011101A (el)
MY (1) MY154495A (el)
NZ (1) NZ581251A (el)
PL (1) PL2143792T3 (el)
PT (1) PT2143792E (el)
RU (1) RU2523596C2 (el)
SI (1) SI2143792T1 (el)
TW (1) TWI468515B (el)
UA (1) UA101806C2 (el)
WO (1) WO2008140126A1 (el)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5540312B2 (ja) * 2008-02-15 2014-07-02 独立行政法人理化学研究所 環状１本鎖核酸複合体およびその製造方法
WO2011143659A2 (en) * 2010-05-14 2011-11-17 Fluidigm Corporation Nucleic acid isolation methods
SG196779A1 (en) 2010-07-08 2014-02-13 Bonac Corp Single-strand nucleic acid molecule for controlling gene expression
US8785121B2 (en) 2010-07-08 2014-07-22 Bonac Corporation Single-stranded nucleic acid molecule for controlling gene expression
US8691782B2 (en) 2010-08-03 2014-04-08 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
AR083445A1 (es) 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
US9115167B2 (en) * 2011-03-10 2015-08-25 Biomics Biotechnologies Co., Ltd. Multi-targets interfering RNA molecules and their applications
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
WO2013077446A1 (ja) * 2011-11-26 2013-05-30 株式会社ボナック 遺伝子発現制御のための一本鎖核酸分子
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP6126088B2 (ja) 2012-05-26 2017-05-10 株式会社ボナック デリバリー機能を有する遺伝子発現制御用の一本鎖核酸分子
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
JP6296434B2 (ja) * 2013-01-25 2018-03-20 国立研究開発法人理化学研究所 機能性核酸分子の構築法
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP6625521B2 (ja) 2013-05-15 2020-01-08 リボカイン，エルエルシー 環状ｒｎａの細胞内翻訳
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CN104419704B (zh) * 2013-09-05 2016-09-14 中国科学院上海生命科学研究院 一种内含子来源环形rna分子及其成环关键核酸序列的应用
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
US10612020B2 (en) 2013-12-26 2020-04-07 Tokyo Medical University Artificial mimic miRNA for controlling gene expression, and use of same
AU2014370829B2 (en) 2013-12-27 2021-03-11 Bonac Corporation Artificial match-type miRNA for controlling gene expression and use therefor
ES2872527T3 (es) 2014-12-27 2021-11-02 Bonac Corp miARN natural para controlar la expresión génica y uso del mismo
JP6602847B2 (ja) 2015-03-27 2019-11-06 株式会社ボナック デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
CN105063210A (zh) * 2015-08-12 2015-11-18 中国农业科学院北京畜牧兽医研究所 一种环状rna的鉴定方法
CN107557363B (zh) * 2016-06-30 2021-03-12 中国科学院分子细胞科学卓越创新中心 可诱导型siRNA表达载体及其制备和应用
EP3604528A4 (en) 2017-03-31 2021-01-13 Bonac Corporation CYCLIC NUCLEIC ACID MOLECULE HAVING A GENE EXPRESSION CONTROL FUNCTION
ES2942575T3 (es) 2017-04-28 2023-06-02 Kyowa Kirin Co Ltd Derivado de oligonucleótido o sal del mismo
EP3642342A4 (en) 2017-06-23 2021-03-17 Cornell University RNA MOLECULES, CIRCULAR RNA PRODUCTION METHODS, AND PROCESSING METHODS
WO2019051563A1 (en) * 2017-09-15 2019-03-21 Commonwealth Scientific And Industrial Research Organisation RNA MOLECULES
CN111201319A (zh) * 2017-10-11 2020-05-26 日东电工株式会社 核酸分子表达的调节
US20200306286A1 (en) 2017-12-15 2020-10-01 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
CN108251424A (zh) * 2017-12-19 2018-07-06 天利康（天津）科技有限公司 一种单链环状rna和dna及其制备方法和应用
CN111819280A (zh) * 2018-03-30 2020-10-23 东丽株式会社 发夹型单链rna分子的制备方法
EP3801639A1 (en) 2018-06-06 2021-04-14 Massachusetts Institute of Technology Circular rna for translation in eukaryotic cells
EP3930683A1 (en) 2019-03-01 2022-01-05 Flagship Pioneering Innovations VI, LLC Compositions, methods, and kits for delivery of polyribonucleotides
ES2928724T3 (es) 2019-03-01 2022-11-22 Flagship Pioneering Innovations Vi Llc Polirribonucleótidos y usos cosméticos de los mismos
CA3128626A1 (en) 2019-03-04 2020-09-10 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides and pharmaceutical compositions thereof
CN113661242A (zh) 2019-03-25 2021-11-16 旗舰创业创新第六有限责任公司 包含经修饰的环状多核糖核苷酸的组合物及其用途
KR20220027855A (ko) 2019-05-22 2022-03-08 매사추세츠 인스티튜트 오브 테크놀로지 원형 rna 조성물 및 방법
AU2020292427A1 (en) 2019-06-14 2022-01-06 Flagship Pioneering Innovations Vi, Llc Circular RNAs for cellular therapy
EP3986469A1 (en) 2019-06-19 2022-04-27 Flagship Pioneering Innovations VI, LLC Compositions comprising circular polyribonucleotides for protein modulation and uses thereof
AU2020296190A1 (en) 2019-06-19 2022-01-06 Flagship Pioneering Innovations Vi, Llc Methods of dosing circular polyribonucleotides
EP3920976B1 (en) 2019-12-04 2023-07-19 Orna Therapeutics, Inc. Circular rna compositions and methods
TW202142239A (zh) 2020-01-29 2021-11-16 美商旗艦先鋒創新有限責任公司 包含環狀多核糖核苷酸之組合物之遞送
US20230181620A1 (en) 2020-01-29 2023-06-15 Flagship Pioneering Innovations Vi, Llc Compositions for translation and methods of use thereof
TW202208629A (zh) 2020-05-20 2022-03-01 美商旗艦先鋒創新有限責任公司 免疫原性組成物及其用途
US20230203192A1 (en) 2020-05-20 2023-06-29 Flagship Pioneering, Inc. Compositions and methods for producing human polyclonal antibodies
EP4153224A1 (en) 2020-05-20 2023-03-29 Flagship Pioneering Innovations VI, LLC Coronavirus antigen compositions and their uses
MX2023002439A (es) 2020-09-03 2023-05-09 Flagship Pioneering Innovations Vi Llc Composiciones immunogénicas y usos de las mismas.
KR102442946B1 (ko) 2021-03-10 2022-09-15 알지노믹스 주식회사 자가 환형화 rna 구조체
CA3229816A1 (en) * 2021-08-27 2023-03-02 Wensheng Wei Constructs and methods for preparing circular rna
AU2022398478A1 (en) 2021-11-24 2024-06-13 Flagship Pioneering Innovations Vi, Llc Coronavirus immunogen compositions and their uses
AU2022397292A1 (en) 2021-11-24 2024-05-30 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
CA3238735A1 (en) 2021-11-24 2023-06-01 Jennifer A. Nelson Immunogenic compositions and their uses
TW202340460A (zh) 2021-12-17 2023-10-16 美商旗艦先鋒創新有限責任公司 用於在變性條件下富集環狀ｒｎａ之方法
TW202340461A (zh) 2021-12-22 2023-10-16 美商旗艦先鋒創新有限責任公司 用於純化多核糖核苷酸之組成物和方法
TW202342064A (zh) 2021-12-23 2023-11-01 美商旗艦先鋒創新有限責任公司 編碼抗融合多肽之環狀多核糖核苷酸
CN115786374B (zh) * 2022-07-06 2023-10-13 广州吉赛生物科技股份有限公司 一种利用鱼腥藻内含子自剪切核酶精准制备环状rna的方法
WO2024097664A1 (en) 2022-10-31 2024-05-10 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
CN116694638A (zh) * 2023-02-20 2023-09-05 天津微环生物医药科技有限责任公司 环状核酸应用-miRNA抑制剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11137260A (ja) 1997-11-06 1999-05-25 Soyaku Gijutsu Kenkyusho:Kk 抗インフルエンザウイルス環状ダンベル型ｒｎａ−ｄｎａキメラ化合物及び抗インフルエンザウイルス剤
US6210931B1 (en) * 1998-11-30 2001-04-03 The United States Of America As Represented By The Secretary Of Agriculture Ribozyme-mediated synthesis of circular RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
AU781598B2 (en) * 1999-04-21 2005-06-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhibiting the function of polynucleotide sequences
WO2003070918A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
ES2728168T3 (es) * 2000-12-01 2019-10-22 Max Planck Gesellschaft Moléculas pequeñas de ARN que median en la interferencia de ARN
WO2003070197A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20040019001A1 (en) * 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
US20090247606A1 (en) * 2001-08-28 2009-10-01 Sirna Therapeutics, Inc. RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADORA1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
CA2457528C (en) * 2002-02-20 2011-07-12 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina)
US7501503B2 (en) * 2002-12-31 2009-03-10 Mcgill University Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase
US20070105108A1 (en) * 2003-06-25 2007-05-10 Somagenics, Inc. Polynucleotides capable of target-depedent circularization and topological linkage
JP4517061B2 (ja) * 2003-08-08 2010-08-04 独立行政法人産業技術総合研究所 ダンベル型ｄｎａの効率的な製造方法
WO2006007569A2 (en) * 2004-07-01 2006-01-19 Somagenics, Inc. Methods of preparation of gene-specific oligonucleotide libraries and uses thereof

Also Published As

Publication number Publication date
WO2008140126A1 (ja) 2008-11-20
PL2143792T3 (pl) 2014-07-31
SI2143792T1 (sl) 2014-05-30
IL201975A (en) 2013-12-31
NZ581251A (en) 2011-11-25
MY154495A (en) 2015-06-30
CN101679962A (zh) 2010-03-24
UA101806C2 (ru) 2013-05-13
HRP20140170T1 (hr) 2014-04-25
KR101525633B1 (ko) 2015-06-03
RU2009145502A (ru) 2011-06-20
AR072034A1 (es) 2010-08-04
KR20100024407A (ko) 2010-03-05
ES2446040T3 (es) 2014-03-06
CA2685994A1 (en) 2008-11-20
EP2143792A1 (en) 2010-01-13
JP2008278784A (ja) 2008-11-20
US20190292538A1 (en) 2019-09-26
BRPI0811440A2 (pt) 2014-10-21
MX2009011101A (es) 2009-12-11
HK1135140A1 (en) 2010-05-28
AU2008250075A1 (en) 2008-11-20
TWI468515B (zh) 2015-01-11
US20180073020A1 (en) 2018-03-15
US20100137407A1 (en) 2010-06-03
DK2143792T3 (da) 2014-04-07
IL201975A0 (en) 2011-08-01
TW200909577A (en) 2009-03-01
AU2008250075B2 (en) 2014-06-19
PT2143792E (pt) 2014-04-03
JP5296328B2 (ja) 2013-09-25
RU2523596C2 (ru) 2014-07-20
EP2143792A4 (en) 2011-08-24
EP2143792B1 (en) 2014-01-08
CO6241167A2 (es) 2011-01-20

Similar Documents

Publication Publication Date Title
CY1115283T1 (el) Μονοκλωνο κυκλικο rna και μεθοδος παραγωγης αυτου
CY1121672T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
EA201991369A1 (ru) Модифицированные направляющие рнк
BRPI0810797A2 (pt) deslocamento cíclico coordenado e salto de sequência para sequências de dispersão zadoff-chu, zadoff-chu modificada, e no sentido de bloco.
CY1120520T1 (el) Συναρμολογηση dna διαμεσολαβουμενη απο νουκλεαση
ATE521434T1 (de) Verfahren zur herstellung geschweisster rund- und profilketten, kettenglied für eine rund- oder profilkette sowie aus solchen kettengliedern aufgebaute rund- oder profilkette
DE602006020056D1 (de) Dimercaptanterminierte polythioetherpolymere und verfahren zu ihrer herstellung und verwendung
BRPI0923648A2 (pt) remoção silenciosa de efusão.
CY1117767T1 (el) Rsv-ειδικα προσδενομενα μορια και μεσα για την παραγωγη αυτων
CY1120136T1 (el) Μεθοδος για την αυξηση της ανοσοδραστικοτητας
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
MX2010006396A (es) Anticuerpos bivalentes, biespecificos.
UA100874C2 (en) Bivalent bispecific antibodies
BRPI0910394A2 (pt) mastigações de animal doméstico de tempo de ocupação aumentado.
IL212099A (en) Bi-specific antibody with single chain CD3 epsilon and prostate-specific membrane antigen, preparations containing them and uses
SG169988A1 (en) Rnai inhibition of alpha-enac expression
ATE499964T1 (de) Trennbare drahtführung
ES2679373T3 (es) Nuevos ligandos de RIG-I y métodos para producirlos
BRPI0906339A2 (pt) condutor de correia.
EA201300513A1 (ru) Волокна для контролируемого разложения
GB0822910D0 (en) Silent chain
WO2009091069A3 (en) Quantum information system
CY1116538T1 (el) Αναλογα ολιγονουκλεοτιδιου τροποποιημενα με φωσφορικο με ανοσοδιεγερτικη δραστικοτητα
BRPI0921972A2 (pt) processo de criação de aves domésticas.
CY1118240T1 (el) ΠΑΡΑΛΛΑΓΕΣ CRIg ΩΡΙΜΑΣΜΕΝΗΣ ΣΥΓΓΕΝΕΙΑΣ